Phase 1 safety trial of FPA144 in patients with gastric cancer in Japan

Trial Profile

Phase 1 safety trial of FPA144 in patients with gastric cancer in Japan

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs FPA 144 (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Aug 2017 According to a Five Prime Therapeutics media release, the completion of this trial is intended to enable the inclusion of Japanese patients in the planned global Phase 3 clinical trial.
    • 17 Jul 2017 According to a Five Prime Therapeutics media release, dosing has been initiated in this trial.
    • 17 Jul 2017 Status changed from planning to recruiting, according to a Five Prime Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top